DOJ Probes Regencell Bioscience After 46,000% Stock Surge
The US Department of Justice is investigating Regencell Bioscience’s extreme stock volatility after its shares skyrocketed 46,000%, prompting questions over trading activity.
/ 920 items
#Healthcare↓
Incyte’s INCB0989 Data Shows Early Promise in Myelofibrosis, Analysts Turn Positive
Incyte’s early INCB0989 myelofibrosis data at ASH 2025 looks encouraging, prompting analyst upgrades and higher price targets from Mizuho, Wells Fargo, and Guggenheim.
William Blair Upgrades Terns Pharmaceuticals to Outperform After Strong TERN-701 Data
William Blair upgraded Terns Pharmaceuticals (TERN) to Outperform following impressive Phase 1 CARDINAL trial results of TERN-701 in chronic myeloid leukemia, showing a 75% overall major molecular response rate and strong safety profile.
TScan Therapeutics Pauses Solid Tumor Trial to Prioritize Heme, and Extends Cash Runway into Second Half of 2027
TScan Therapeutics (TCRX) announced a major strategic shift, securing FDA alignment for its pivotal TSC-101 trial for blood cancers, improving manufacturing speed, and cutting costs to extend its financial health into the second half of 2027.
FDA Feedback Rocks uniQure: Gene Therapy for Huntington’s Disease Delayed
UniQure's stock plummeted after the FDA unexpectedly decided that the current clinical trial data for its promising Huntington's disease therapy, AMT-130, is not adequate for immediate marketing application (BLA).
Caribou Vispa-cel Efficacy Matches Autologous CAR-T Therapy
Positive Phase 1 trial data for vispa-cel, an allogeneic (off-the-shelf) CAR-T cell therapy, demonstrates efficacy and durability comparable to traditional autologous treatments, potentially broadening access for patients with large B cell lymphoma.